Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
05 Avril 2023 - 1:46PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of April 2023
Commission File Number: 001-37452
CELYAD ONCOLOGY SA
(Translation of registrants name into English)
Rue Edouard
Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Celyad Oncology SA
On April 4, 2023, Celyad Oncology SA (the Company) issued a press release announcing receipt of a letter (the
Letter) from The Nasdaq Stock Market (Nasdaq) on March 31, 2023, informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq
Global Market, which requires that a listed companys stockholders equity be at least $10.0 million (the Stockholders Equity Requirement).
The Company has a period of 45 calendar days from the date of the Letter, or until May 15, 2023, to submit a plan to regain compliance with the
Stockholders Equity Requirement. If such a plan is submitted and accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Letter for the Company to regain compliance.
A copy of the Companys press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information contained in this Current Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by
reference into the Companys Registration Statements on Forms F-3 (File No. 333-248464) and S-8 (File No. 333-220737).
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CELYAD ONCOLOGY SA |
|
|
|
|
Date: April 5, 2023 |
|
|
|
By: |
|
/s/ Michel Lussier |
|
|
|
|
|
|
Michel Lussier |
|
|
|
|
|
|
Interim Chief Executive Officer |
Celyad (CE) (USOTC:CLYYF)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Celyad (CE) (USOTC:CLYYF)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024
Real-Time news about Celyad SA (CE) (OTCMarkets): 0 recent articles
Plus d'articles sur Celyad Oncology Sa